Cardiotoxicity of Chemotherapeutic Agents
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Toxicology".
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 3349
Special Issue Editor
2.Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV)， Madrid, Spain
3.Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS) , Santiago de Compostela, Spain
Interests: cardiotoxicity; biomarkers; microRNA; cardiac imaging
Special Issue Information
Dear Colleagues,
Continuous advances in the early detection and treatment of cancer have increased overall survival in recent decades. However, it is now well-established that cancer patients and long-term survivors face an increased cardiovascular (CV) morbimortality associated with chemotherapeutic agents. Cardiotoxicity (CT) is currently recognized as a main side effect of chemotherapy. Left ventricular (LV) dysfunction and/or heart failure (HF) are the most common cardiovascular complications after the administration of chemotherapies. As HF may limit optimal cancer treatment, the early detection of myocardial dysfunction during chemotherapy is a major issue. The current context demands greater efforts in clinical and basic research to improve our understanding of the etiopathology of CT. In-depth knowledge of CT-associated pathophysiological mechanisms will allow a suitable cardiovascular risk stratification of cancer patients to be established and early diagnosis tools and novel cardioprotective strategies to be identified.
This Special Issue intends to provide the reader with a better understand of the relationship between cancer therapies and CV toxicity. Overall, we are confident that this Special Issue will be of interest to the scientific community and will help to expand our current knowledge on chemotherapy-associated cardiotoxicity.
Dr. Ricardo Lage Fernández
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiotoxicity
- chemotherapy
- biomarkers
- cardiac imaging
- global longitudinal strain
- heart failure
